Inactive Instrument

News BioLight Life Sciences Ltd. TEL AVIV STOCK EXCHANGE

Equities

BioLight Life Sciences : Calling of Special Meeting for May 9, 2024 - Company announcement	04-01	PU
BioLight Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
BioLight Life Sciences : Calling of Annual Meeting for April 8, 2024 - Company announcment	03-04	PU
BioLight Life Sciences Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Diagnostear, a subsidiary of BioLight Life Sciences Ltd, signed a binding Letter of Intent for merger, capital raise and listing on the Canadian Securities Exchange	23-06-12	PR
BioLight Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
BioLight Life Sciences Announces Results from its Glaucoma Insert VS101 Phase 1/2A Clinical Trial	17-07-24	CI
DiagnosTear Ltd. to Provide Analysis Services Through its TeaRx Multi-Parameter Diagnostic Assays for Use in an Clinical Trial for Dry Eye Syndrome	17-02-23	CI
A Chinese investor signed Memorandum of Understanding to acquire 45% stake in BioLight Life Sciences Ltd. from public for ILS 19.4 million.	16-12-28	CI
BioLight Reports Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test	16-07-26	CI
BioLight Life Sciences Ltd. Receives worldwide rights for Eye Drops for Dry Eye Syndrome	16-05-19	CI

No results for this search